NEW YORK (360Dx) – Antibiotic susceptibility testing firm SeLux Diagnostics announced today it has signed a contract with the Biomedical Advanced Research and Development Authority for up to $45 million.

The Boston-based firm will receive $9.3 million upfront to fund a clinical trial for its NGP next-generation phenotyping platform. SeLux is eligible for an additional $36 million, contingent on it meeting certain milestones, for the development of a second-generation rapid sepsis diagnostic platform, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.